PharmaJet presents latest Research Results at World Vaccine Congress

Tuesday, May 7, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

Superior efficacy cited with Needle-free delivery of novel pharmaceuticals and immunotherapeutics

GOLDEN, Colo., May 7, 2019 /PRNewswire/ -- PharmaJet®, the maker of innovative, needle-free injection

technology, today shared that their latest research results were presented at the World Vaccine Congress on April 16, in Washington DC at the Renaissance Washington DC Downtown Hotel.  The presentation, entitled Expanding Vaccine Effectiveness with Needle-free Delivery, was presented by Dr. Marilyn Dysart, Clinical Affairs Manager at PharmaJet, Inc.

The PharmaJet injection technology has been proven safe and effective with commercial vaccines and pharmaceuticals including influenza, MMR, HPV, polio, and others.  In addition, an increasing amount of data is showing superior efficacy over other delivery methods with nucleic acid-based platforms for vaccines, passive antibodies, and personalized medicine. 

The Needle-free devices have gained regulatory clearances both in the US and Europe, and in various other markets, and they are also pre-qualified (PQS) by the World Health Organization.

"The PharmaJet devices are now in use with over 50 novel pharmaceuticals, mostly Nucleic acid platforms, in pre-clinical and clinical studies globally, and the data has continued to show robust safety and overwhelmingly positive clinical efficacy," said Ron Lowy, Chairman and Chief Executive Officer, PharmaJet, Inc. "Our collaborators are using this technology to enable their transition from animal studies into human trials and potential licensure."

For more information about PharmaJet visit www.pharmajet.com.

Refer to Instructions for Use to ensure safe injections and to review risks.

1 Data on file

About PharmaJetBased in Golden, Colorado, PharmaJet's mission is worldwide acceptance of PharmaJet needle-free devices as a standard of care in the vaccine delivery market. The innovative Stratis® Injector has U.S. FDA 510(k) marketing clearance, CE Mark and WHO PQS certification to deliver medications and vaccines either intramuscularly or subcutaneously.  The Tropis® device for intradermal injections received authorization to apply the CE Mark in May 2016.  The PharmaJet Needle-free Injectors are safe, fast and easy-to-use.  They eliminate needlestick injuries, needle reuse and cross contamination, and help reduce sharps waste disposal. For more information, visit www.pharmajet.com.

CONTACT:Nancy LillieNancy.Lillie@pharmajet.com1-888-900-4321 Option 3

 

Cision View original content:http://www.prnewswire.com/news-releases/pharmajet-presents-latest-research-results-at-world-vaccine-congress-300841278.html

SOURCE PharmaJet



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store